JMP Securities Reiterates Market Outperform on Clearside Biomedical, Maintains $5 Price Target
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Jonathan Wolleben has reiterated a Market Outperform rating on Clearside Biomedical (NASDAQ:CLSD) and maintained a $5 price target.
July 12, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Clearside Biomedical's stock may see positive movement as JMP Securities maintains a Market Outperform rating and a $5 price target.
Analyst ratings and price targets can significantly influence investor sentiment and stock price. The reiteration of a Market Outperform rating and a $5 price target by JMP Securities suggests confidence in Clearside Biomedical's performance, potentially leading to increased investor interest and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100